Eplerenone is an effective antihypertensive that reduces morbidity and mortality in individuals with left ventricular dysfunction post myocardial infarction, though it can cause hyperkalemia.
Eplerenone is a specific mineralocorticoid receptor antagonist effective for hypertension and post-MI heart failure, though hyperkalemia requires monitoring.
Eplerenone is an aldosterone receptor antagonist indicated for the treatment of hypertension and congestive heart failure. Eplerenone contains an epoxy group, which offers greater mineralocorticoid receptor specificity. It is an effective antihypertensive that has been shown to reduce morbidity and mortality in individuals with left ventricular dysfunction post myocardial infarction. Studies are continuing to determine whether the benefit of mineralocorticoid receptor blockade in advanced congestive heart failure is also observed when eplerenone treatment is initiated in earlier stages of the disease. The most common side effect is hyperkalemia necessitating close monitoring in individuals with diabetes and proteinuria, heart failure or in those who are taking moderate CYP450 3A4 inhibitors. It is category B in pregnancy.
Muldowney et al. (Wed,) conducted a review in Hypertension and congestive heart failure. Eplerenone was evaluated. Eplerenone is an effective antihypertensive that reduces morbidity and mortality in individuals with left ventricular dysfunction post myocardial infarction, though it can cause hyperkalemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: